May 15th 2024
For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
FDA Expands Label for Pembrolizumab to Include Treatment of Locally Advanced cSCC
July 6th 2021The FDA has expanded its approval for pembrolizumab monotherapy to include the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.
Read More
Increased Responses to Lifileucel Plus Pembrolizumab Observed in Patients With Advanced Melanoma
June 4th 2021In patients with pre-immune checkpoint inhibitor-naïve advanced melanoma, treatment with the combination of lifileucel plus pembrolizumab, compared to pembrolizumab alone, increased the overall response rate.
Read More
Initial Treatment With Tebentafusp Show Significant OS Improvement in Metastatic Uveal Melanoma
April 10th 2021In patient with metastatic uveal melanoma, frontline treatment with tebentafusp achieved significant and clinically meaningful improvement in overall survival, according to data from the phase 3 IMCgp100-202 trial.
Read More
Experts Contemplate Realistic Treatment Goals Using Hedgehog Inhibitors in Basal Cell Carcinoma
March 26th 2021Hedgehog inhibitors are becoming more widely used for Basal cell carcinoma. Two experts, Shailender Bhatia, MD and Paul T. Nghiem, MD, PhD discussed the reality of hedgehog inhibitor use in practice during a virtual Targeted Oncology Case-Based Roundtable event.
Read More
Tilsotolimod Plus Ipilimumab Shows Suboptimal Responses in Anti–PD-1 Refractory Advanced Melanoma
March 19th 2021The combination of tilsotolimod and ipilimumab demonstrated a low objective response rate in patients with anti–PD-1–refractory advanced melanoma, missing the coprimary end point of the phase 3 ILLUMINATE-301 trial.
Read More
FDA Approves Cemiplimab for Locally Advanced and Metastatic Basal Cell Carcinoma
February 9th 2021The FDA has approved cemiplimab-rwlc, the PD-1 inhibitor, for the treatment of patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog inhibitor is not appropriate.
Read More
Rabinowits Analyzes the Use of Anti–PD-1 Therapy in cSCC
February 1st 2021During a Targeted Oncology Case-Based Peer Perspectives event, Guilherme Rabinowits, MD, medical oncologist/hematologist, Miami Cancer Institute, discussed the case of 69-year-old patients with cutaneous squamous cell carcinoma.
Read More
FDA Grants Fast Track Designations in Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
January 12th 2021The FDA granted 2 Fast Track designations to the cavrotolimod for 2, including in combination with anti-PD-1 therapy in patients with locally advanced or metastatic Merkel cell carcinoma who are refractory to prior anti-PD-1 blockade and in combination with anti-PD-1/PD-L1 in patients with locally advanced or metastatic cutaneous squamous cell carcinoma who are refractory to prior anti-PD-1/PD-L1 blockade.
Read More
Systemic Therapy Remains a Successful Strategy for Patients Refusing Surgery for CSCC
January 11th 2021For patients with cutaneous squamous cell carcinoma who refuse surgery as a treatment for their disease, systemic therapies like cemiplimab, nivolumab, avelumab, and pembrolizumab can still improve outcomes, explained Asim Amin, MD, PhD, a medical oncologist, Levine Cancer Institute. Atrium Health during a Targeted Oncology Case-Based Peer Perspectives event.
Read More
Expert Compares Vismodegib and Sonidegib for Treatment of Infiltrative BCC
January 7th 2021Solly Chedid, MD, led a discussion with a group of peers about the treatment of infiltrative basal cell carcinoma in a 88-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.
Read More
Exploring Options for First- and Second-Line Therapies in cSCC
December 31st 2020The plan of treatment for a 69-year-old patient with poorly differentiated, infiltrative, cutaneous squamous cell carcinoma was the topic of discussion among Dan Paul Zandberg, MD, and other clinicians in attendance during a Targeted Oncology Case-Based Peer Perspectives event.
Read More
Emerging Data May Provide More Options for Systemic Treatment of Basal Cell Carcinoma, Says In
November 12th 2020During a Targeted Oncology Case Based Peer Perspective event, Gino K. In, MD, MPH, assessed the risk status of an 88-year-old patient with basal cell carcinoma and discussed treatment options.
Read More
Spartalizumab Triplet Does Not Improve PFS in Metastatic Melanoma
September 20th 2020The phase 3 COMBI-I clinical trial of spartalizumab plus dabrafenib and trametinib showed no improvement in investigator-assessed progression-free survival in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, missing the primary end point in part 3 of the study.
Read More